Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina
Tóm tắt
Objectives: To perform an evaluation from the societal perspective of the cost of treatment with enoxaparin sodium versus unfractionated heparin (UFH) in patients with unstable angina and non-Q wave myocardial infarction in France.
Design: Four complementary cost-minimisation analyses based on the results of the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events (ESSENCE) international trial were conducted. We assessed differences in medical resource consumption and in duration of hospital stay in the whole study population (n = 3171) and for the French patients (n = 133).
Results: Resultswere consistent for the study group as a whole and for the French subgroup. Among patients treated with enoxaparin sodium, there was a statistically significant reduction in the use of angiography and percutaneous transluminal coronary angioplasty (whole group study: p = 0.024 and 0.006, respectively) and a trend towards shorter lengths of hospital stay. The differences in angiography and angioplasty rates led to estimated average net cost savings with enoxaparin sodium of French Francs (FF)1555 per treated patient (whole study population) and FF9993 (French subgroup) [1996 values]. The analyses based on the duration of hospital stay resulted in estimated net cost savings with enoxaparin sodium of between FF1014 per treated patient (whole study population) and FF2804 (French subgroup).
Conclusion: Our study confirmed earlier results which show that enoxaparin sodium is cost saving in the treatment of unstable angina.
Tài liệu tham khảo
Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11
Wallentin L, RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30
Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90 (1): 613–22
Cairns JA, Lewis HD, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest 1995; 108: 380–400
Hirsch J. Low-molecular-weight heparin: a review of the results of recent studies on the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575–82
Cohen M, Demers C, Gurkinkel EP, the ESSENCE Study Group, et al. A comparison of low-molecular weight heparin with unfractioned heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–52
Mark DB, Cowper PA, Berkowitz S, et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionned heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702–7
Unger F. European survey on cardiac interventions, open heart surgery, PTCA, and cardiac catheterisation 1993. Report of the Institute for Cardiac Survey of the European Academy of Sciences and Arts. Ann Eur Acad Sci Arts 1994; 8: 1–154
Van den Brand M, the European Angioplasty Survey Group. Utilization of coronary angioplasty and cost of angioplasty disposables in 14 western European countries. Eur Heart J 1993; 14: 391–7
Röthlisberger C, Meier B, the Working Group on Coronary Circulation of the European Society of Cardiology. Coronary interventions in Europe 1992. Eur Heart J 1995; 16: 922–9
Selby JV, Fireman BH, Lundstrom RJ, et al. Variation among hospitals in coronary angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med 1996; 335 (25): 1888–96
Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5: 92–105
Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute conronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999; 16 (5 Pt 2): 533–42
Aden G. Fertigspritzen versus Ampullen: ein Anwendungsvergleich. Krankenhauspharmazie 1992; 5: 3–7
Fabregas X, Garcia B, Jimenez I. Prefilled syringes: a valuable addition to the pharmacy. Int Pharm J 1996; 10: 138–9
Cohen M, Bigonzi F, Le Louer V, the ESSENCE Group, et al. One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-Wave myocardial infarction) [abstract]. JAmColl Card 1998; 31 Suppl. A: 820–2
Klein W, Buchwald A, Hillis SE, the FRIC investigators et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61–8